Neurizon Therapeutics (ASX:NUZ) Research & Development: A$14.28 Mil (TTM As of Dec. 2025)


What is Neurizon Therapeutics Research & Development?

Neurizon Therapeutics ASX:NUZ Research & Development is A$14.28 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Neurizon Therapeutics's Research & Development for the six months ended in Dec. 2025 was A$8.24 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$14.28 Mil.

Neurizon Therapeutics  (ASX:NUZ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Neurizon Therapeutics Research & Development Related Terms

Neurizon Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Research & Development Chart

Neurizon Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.76 1.03 3.85 11.68

Neurizon Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 2.52 5.64 6.04 8.24

Neurizon Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$14.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$14.28 Mil mean?
Neurizon Therapeutics (ASX:NUZ) has a Research & Development of A$14.28 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Neurizon Therapeutics and its competitors.
Is Neurizon Therapeutics' Research & Development too high?
Neurizon Therapeutics' current Research & Development is A$14.28 Mil.
How does Neurizon Therapeutics' Research & Development compare to VRTX and REGN?
Neurizon Therapeutics' Research & Development of A$14.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Neurizon Therapeutics and its competitors. Neurizon Therapeutics's current Research & Development is A$14.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (ASX:NUZ) has a current Research & Development of A$14.28 Mil. The current Research & Development is A$14.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Neurizon Therapeutics (ASX:NUZ), the current Research & Development is A$14.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:Germany
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).